Mutations that permit residual CFTR function delay acquisition of multiple respiratory pathogens in CF patients

被引:70
作者
Green, Deanna M. [2 ]
McDougal, Kathryn E. [3 ]
Blackman, Scott M. [1 ]
Sosnay, Patrick R. [1 ]
Henderson, Lindsay B. [1 ]
Naughton, Kathleen M. [1 ]
Collaco, J. Michael [2 ]
Cutting, Garry R. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21218 USA
[2] Johns Hopkins Univ, Sch Med, Div Pediat Resp Sci, Baltimore, MD USA
[3] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
基金
美国国家卫生研究院;
关键词
CYSTIC-FIBROSIS; PSEUDOMONAS-AERUGINOSA; LUNG-DISEASE; GENETIC MODIFIERS; MORTALITY; CONSEQUENCES; REGULATOR; INFECTION; CHILDREN;
D O I
10.1186/1465-9921-11-140
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Lung infection by various organisms is a characteristic feature of cystic fibrosis (CF). CFTR genotype effects acquisition of Pseudomonas aeruginosa (Pa), however the effect on acquisition of other infectious organisms that frequently precede Pa is relatively unknown. Understanding the role of CFTR in the acquisition of organisms first detected in patients may help guide symptomatic and molecular-based treatment for CF. Methods: Lung infection, defined as a single positive respiratory tract culture, was assessed for 13 organisms in 1,381 individuals with CF. Subjects were divided by predicted CFTR function: 'Residual': carrying at least one partial function CFTR mutation (class IV or V) and 'Minimal' those who do not carry a partial function mutation. Kaplan-Meier estimates were created to assess CFTR effect on age of acquisition for each organism. Cox proportional hazard models were performed to control for possible cofactors. A separate Cox regression was used to determine whether defining infection with Pa, mucoid Pa or Aspergillus (Asp) using alternative criteria affected the results. The influence of severity of lung disease at the time of acquisition was evaluated using stratified Cox regression methods by lung disease categories. Results: Subjects with 'Minimal' CFTR function had a higher hazard than patients with 'Residual' function for acquisition of 9 of 13 organisms studied (HR ranging from 1.7 to 3.78 based on the organism studied). Subjects with minimal CFTR function acquired infection at a younger age than those with residual function for 12 of 13 organisms (p-values ranging: < 0.001 to 0.017). Minimal CFTR function also associated with younger age of infection when 3 alternative definitions of infection with Pa, mucoid Pa or Asp were employed. Risk of infection is correlated with CFTR function for 8 of 9 organisms in patients with good lung function (> 90%ile) but only 1 of 9 organisms in those with poorer lung function (< 50%ile). Conclusions: Residual CFTR function correlates with later onset of respiratory tract infection by a wide spectrum of organisms frequently cultured from CF patients. The protective effect conferred by residual CFTR function is diminished in CF patients with more advanced lung disease.
引用
收藏
页数:9
相关论文
共 30 条
  • [1] Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas
    Ahmed, N
    Corey, M
    Forstner, G
    Zielenski, J
    Tsui, LC
    Ellis, L
    Tullis, E
    Durie, P
    [J]. GUT, 2003, 52 (08) : 1159 - 1164
  • [2] Cystic fibrosis transmembrane conductance regulator and caveolin-1 regulate epithelial cell internalization of Pseudomonas aeruginosa
    Bajmoczi, Milan
    Gadjeva, Mihaela
    Alper, Seth L.
    Pier, Gerald B.
    Golan, David E.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2009, 297 (02): : C263 - C277
  • [3] Genetic Modifiers Play a Substantial Role in Diabetes Complicating Cystic Fibrosis
    Blackman, Scott M.
    Hsu, Stephanie
    Vanscoy, Lori L.
    Collaco, J. Michael
    Ritter, Sarah E.
    Naughton, Kathleen
    Cutting, Garry R.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (04) : 1302 - 1309
  • [4] Courtney J M, 2004, J Cyst Fibros, V3, P93, DOI 10.1016/j.jcf.2004.01.005
  • [5] Cystic Fibrosis Foundation, 2008, PAT REG 2008 ANN REP
  • [6] Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis
    Dasenbrook, Elliott C.
    Merlo, Christian A.
    Diener-West, Marie
    Lechtzin, Noah
    Boyle, Michael P.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 178 (08) : 814 - 821
  • [7] Achromobacter xylosoxidans in cystic fibrosis:: Prevalence and clinical relevance
    De Baets, Frans
    Schelstraete, Petra
    Van Daele, Sabine
    Haerynck, Filomeen
    Vaneechoutte, Mario
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2007, 6 (01) : 75 - 78
  • [8] Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis:: a European consensus
    Döring, G
    Conway, SP
    Heijerman, HGM
    Hodson, ME
    Hoiby, N
    Smyth, A
    Touw, DJ
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2000, 16 (04) : 749 - 767
  • [9] Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis
    Emerson, J
    Rosenfeld, M
    McNamara, S
    Ramsey, B
    Gibson, RL
    [J]. PEDIATRIC PULMONOLOGY, 2002, 34 (02) : 91 - 100
  • [10] Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report
    Farrell, Philip M.
    Rosenstein, Beryl J.
    White, Terry B.
    Accurso, Frank J.
    Castellani, Carlo
    Cutting, Garry R.
    Durie, Peter R.
    LeGrys, Vicky A.
    Massie, John
    Parad, Richard B.
    Rock, Michael J.
    Campbell, Preston W., III
    [J]. JOURNAL OF PEDIATRICS, 2008, 153 (02) : S4 - S14